The submission to the US FDA has been initiated and they intend to file these data with the European Medicines Agency and other regulatory bodies in the coming weeks
Trillium’s portfolio includes biologics that are designed to enhance the ability of patients’ innate immune system to detect and destroy cancer cells
XELJANZ is the first and only Janus kinase (JAK) inhibitor approved in Europe for the treatment of polyarticular JIA and juvenile PsA and has received regulatory approval in four indications in the European Union, the most of any JAK inhibitor
The vaccine will now be marketed as Comirnaty (koe-mir’-na-tee), for the prevention of Covid-19 disease
The data suggest that a booster dose given within 6 to 12 months after the second dose may help maintain a high level of protection against COVID-19.
The company posted net profit of Rs.124.45 crores for the period ended June 30, 2020.
The companies anticipate clinical studies to begin in August, subject to regulatory approvals
Adjusted PAT declined 18.8% YoY
Revenue from operations for the year ended March 31, 2021 is ?2,239 crore
The company has posted net profit of Rs.397.06 crores for the 9 months period ended December 31, 2020.
Subscribe To Our Newsletter & Stay Updated
